NIDA Research Education Grants in Drug Abuse and Addiction (R25) | Apply Online

Opportunity Summary:

The NIDA Research Education Grants in Drug Abuse and Addiction (R25) opportunity (Funding Opportunity Number PAR-07-221) is a National Institutes of Health grant program run by the National Institute on Drug Abuse (NIDA) to strengthen clinically focused education, curriculum development, and research program capacity in the areas of drug abuse and addiction. The central aim is to build and improve programs that help develop the next generation of clinical and health services researchers, particularly by enhancing structured learning experiences, research exposure, and other educational components that expand the field's research workforce and infrastructure. This mechanism is meant to support program building rather than function as a long-term individual training or career pathway award.

A key feature of this R25 is that it can provide participant support in the form of salary or subsistence allowances, but NIDA is explicit that the grant should not be used as long-term support for any one participant. In practical terms, if an individual receives support for more than two years, NIDA may treat that as long-term support, which would blur the line between an education grant and more traditional training mechanisms. Because of that, applicants are expected to plan participant involvement accordingly, and if there is a compelling reason to support someone beyond two years, the applicant must obtain prior written approval from NIDA before extending that support past the two-year point. This restriction also highlights how the R25 differs from mechanisms such as the Ruth L. Kirschstein National Research Service Award (NRSA) and career development awards, which are specifically designed to provide longer, more continuous support for trainees or early-career researchers.

From an administrative standpoint, this opportunity is categorized as a discretionary grant with an activity focus spanning education and health. It is tied to CFDA number 93.279 (Drug Abuse and Addiction Research Programs). There is no cost sharing or matching requirement listed, which generally means applicants are not required to commit non-federal matching funds as a condition of eligibility, though standard NIH budget and allowability rules would still apply.

Eligibility includes a broad range of domestic organizations and certain government entities. Eligible applicants include public and state-controlled institutions of higher education, private institutions of higher education, nonprofit organizations (including both 501(c)(3) and certain non-501(c)(3) nonprofits other than institutions of higher education), and state governments. The announcement also specifies that eligible agencies of the Federal Government may apply, and that faith-based and community-based organizations are eligible as well, as long as they otherwise meet NIH eligibility requirements. Foreign institutions are not eligible to apply, which means the applicant organization must be based in the United States, even if some program activities involve international collaboration consistent with NIH rules.

The timeline information in the posting reflects that the announcement operated with multiple receipt dates rather than a single deadline, with the posting date listed as February 16, 2007. The current closing date shown in the source data is April 21, 2010, and the archive date is May 21, 2010, indicating that this specific announcement is no longer active as of that archival date. Applicants looking for a current version would typically need to search the NIH Guide for Grants and Contracts or Grants.gov for an updated R25 announcement from NIDA, since agencies often reissue or replace program announcements over time.

For full details, the source points to the NIH Guide announcement page at http://grants.nih.gov/grants/guide/pa-files/PAR-07-221.html, and provides the NIH Office of Extramural Research (OER) webmaster email (FBOWebmaster@OD.NIH.GOV) for technical issues accessing or linking to the announcement.

Browse more: Education Grants, Education Loans, Pell Grants

Browse more business programs for Drug Abuse Research and Prevention

Browse more opportunities from the same agency: National Institutes of Health

Browse more opportunities from the same category: Education Health

Next opportunity: Pilot and Feasibility Studies on Oral Health Promotion Research across the Life Span (R21)

Previous opportunity: Fragile X Pre mutation and Ovarian Function (R03)

USGrants.org Applicant Portal:

Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.

Apply for PAR 07 221

 

[Watch] how do funding administrators access proposals?

Applicants also applied for:

Applicants who have applied for this opportunity (PAR 07 221) also looked into and applied for these:

 

Grant application guides and resources

It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!

Apply for Grants

 

 

Premium leads for funding administrators, grant writers, and loan issuers

Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.

If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.

Subscribe to Leads

 

Request more information:

Would you like to learn more about this funding opportunity, similar opportunities to "PAR 07 221", eligibility, application service, and/or application tips? Submit an inquiry below:

Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.